Table 6.
Female | Male | P value for treatment effect | ||||||
---|---|---|---|---|---|---|---|---|
CON | FGRS | FGRI | CON | FGRS | FGRI | |||
n = 12 | n = 15 | n = 13 | n = 20 | n = 11 | n = 14 | Female | Male | |
BMC (g) | 96 ± 5 | 78 ± 4 | 83 ± 4 | 104 ± 4 | 92 ± 6 | 91 ± 5 | 0.04* | ns |
BMD (g cm−2) | 0.53 ± 0.02 | 0.45 ± 0.01 | 0.46 ± 0.01 | 0.53 ± 0.01 | 0.49 ± 0.02 | 0.50 ± 0.02 | <0.01*† | ns |
LM (kg) | 6.3 ± 0.3 | 5.5 ± 0.2 | 5.7 ± 0.3 | 7.0 ± 0.3 | 6.1 ± 0.4 | 6.2 ± 0.3 | 0.08 | 0.06 |
Bone mineral content (BMC), bone mineral density (BMD) and lean mass (LM) measured by dual X‐ray absorptiometry. Data are means ± SEM. Symbols denote significant differences amongst experimental groups on post hoc testing: *CON vs. FGRS; †CON vs. FGRI; ns, not significant.